We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Advisory Committee Votes 14-1 Against Adding Mortality Data for GSK’s Trelegy Ellipta
Advisory Committee Votes 14-1 Against Adding Mortality Data for GSK’s Trelegy Ellipta
GlaxoSmithKline failed yesterday to convince an FDA advisory committee that it should be allowed to add study data showing a reduction in mortality to the label of its chronic obstructive pulmonary disease (COPD) drug Trelegy Ellipta.